Products

switchplex t790m visual

HB SwitchPlex™

T790M Kit

EGFR T790M Mutation test

RUO

Principle

Lung Cancer and EGFR T790M Mutation

    About 85% of Lung cancer is Non Small Cell Lung Cancer (NSCLC), and 70% of NSCLC is caused by overexpression of epidermal growth factor receptor gene.

EGFR tyrosine kinase inhibitor (TKI) treatment significantly delays the progression of NSCLC, however, exon 20 T790M mutation is related to the acquired tolerance to TKI treatment. Therefore, patient prescribed with Gefitinib or Erlotinib needs regular monitoring of EGFR T790M mutation tests and patients with test positive for the mutation needs to change the prescription to Osimertinib.

First-Line
Resistance
Second-Line

First-Line Treatment

Tyrosine Kinase Inhibitors (TKIs)

efr_iressa

▲ Iressa

(gefitinib)

egfr_tarceva

▲ Tarceva

(erlotinib)

※ Image source: Asan Medical Center (https://ni.amc.seoul.kr/asan/healthinfo/druginfo)

Edit Template

First-Line Treatment

Approximately, 50% of patients develop Resistance in 6 months.

Edit Template

Second-Line Treatment

※ Image source: Asan Medical Center (https://ni.amc.seoul.kr/asan/healthinfo/druginfo)

Edit Template

EGFR TKI resistance occur in 50% of NSCLC patients within 6 months due to EGFR T790M mutation.

Mutation positive patients need proper prescription

for targeted agents to treat the somatic mutation in early variation.

Related Technology

switching_img01

HB SwitchPlex™ products are applied with Switching™-PCR Technology which detects target genes in low concentrations with high reproducibility and accuracy

(<10¹ copies PCR Template)

ktc_logo
ktc_cert1
ktc_cert2

High Sensitivity

4 copies / rxn(gDNA) : 100%

2 copies / rxn(gDNA) :   80%

Internationally certified Korea Testing Certification institute (KTC) confirmed the Limit of Detection (L.O.D) for HB SwitchPlex™ T790M Kit

*KTC : Korea Testing Certification Institute